Abstract 2927
Background
Cancer, which is included in the scope of chronic diseases, affects the lifestyle and quality of the individuals, who got diagnosed, and their familes due to the disease course and treatment method. According to the "theory of family systems", when a disease occurs in the individual, the whole family is affected by the disease, not only patient. It is suggested that families should not be seen as a passive shelter for patients, they should also as a human unity living at the same time as the cancer crisis. In cancer care, caregivers have many responsibilities, from diagnosis to the end of life. While there are studies conducted to evaluate the quality of life of cancer patients in Turkey and other countries, there are a limited number of studies evaluating the quality of life of caregivers of cancer patients. It was aimed to performed in our country for validity and reliability of "Singapore Caregiver Quality Of Life Scale", which was planned based on this deficiency, and to be a guide for the evaluation of the quality of the life of the relatives or carers of different cultures, different ethnic groups and determining the nursing care strategies.
Methods
This study, which was planned as a methodological and descriptive study, was caried out with 550 caregivers in two university hospitals in Izmir. The data were collected by using the Individual Presentation Form, Singapore Caregiver Quality of Life Scale and Quality of Life Scale in Cancer Patients Family Version. Written informed consent was obtained from hospitals and individuals.
Results
The analysis of the findings is ongoing and will be shared in the full text.
Conclusions
Quality of life of caregivers of cancer patients is an important indicator of the quality of life of the patient. In this study, Turkish validation sfudies of the "Singapore Caregiver Quality Of Life Scale" were conducted. The results will be shared later.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract